Forecast

There is no analyst data available for this company.

News Go to news feed

Merck: €1,000 investment three years ago now about 15.5% down

Someone who bought €1,000 of Merck shares at the closing price of €166.00 three years ago would now have 6.024 shares in their portfolio. At a price of €140.25 on 28.08.2026 the investment is worth €844.88, a decline of 15.51%. All Merck shares most recently had a market value of €60.98 billion; stock splits and dividends were not taken into account in the calculation. » More on finanzen.net
Merck climbs to record high after positive phase-3 data for personalized mRNA cancer therapy

Merck reported Q2 revenue growth but recorded a net loss due to a one-time R&D charge from the acquisition of Terns. Together with Moderna, Merck released positive phase-3 results for a personalized mRNA therapy in resected melanoma that significantly delayed recurrence and distant metastases. The data pushed the stock to a record high and could open long-term new growth opportunities for Keytruda combinations and a new therapy platform. » More on finanzen.net
Merck reaches 52-week high after positive phase-3 result for cancer vaccine

Merck's stock rose about 3.4% in the morning to $154.03 and reached a new 52-week high of $154.49. The catalyst was the phase-3 data from the INTerpath-001 trial of Intismeran Autogen, a personalized mRNA vaccine against melanoma, which met the primary endpoint of recurrence-free survival and a key secondary endpoint of distant-metastasis-free survival in high-risk patients. The combination of Intismeran with Keytruda showed significantly better efficacy than Keytruda alone. Several analysts therefore raised their ratings and price targets markedly, strengthening the revaluation of Merck's growth prospects ahead of Keytruda's expected patent expiry in 2028. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Merck Gruppe has already paid €2.20 in dividends. The last payout was in April.

Financials

In the last quarter, Merck Gruppe had revenue of €5.43B and net profit of €489.27M

(EUR)	Jun 2026	YoY
Revenue	5.43B	3.25%
Gross profit	3.16B	4.44%
Net profit	489.27M	24.96%
EBITDA	1.73B	26.70%

Fundamentals

Metric	Value
Market capitalization	€61.43B
Number of shares	434.78M
52-week high/low	€151.15 - €100.46
Dividend yield	1.57%
Dividends TTM	€2.20
Beta	0.83
P/E ratio	25.73
PEG ratio	-1.50
P/B ratio	2.02
P/S ratio	2.88

Company profile

Die MERCK Kommanditgesellschaft auf Aktien ist weltweit in den Bereichen Gesundheitswesen, Biowissenschaften und Elektronik tätig. Sie erforscht, entwickelt, produziert und vermarktet pharmazeutische und biologische verschreibungspflichtige Medikamente zur Behandlung von Neurologie und Immunologie, Onkologie, Fruchtbarkeit sowie kardiologischem Stoffwechsel und Endokrinologie. Das Unternehmen liefert auch Produkte, Werkzeuge und Dienstleistungen für Forschungslabors, die Pharma- und Biotech-Produktion sowie für Industrie- und Testlabors. Darüber hinaus bietet es Material für integrierte Schaltkreise, Flüssigkristalle, organische Leuchtdioden, Fotolacke, intelligente Antennen und Flüssigkristall-Verglasungslösungen sowie Effektpigmente für den Einsatz in Autolacken, Kosmetika, Industrie- und Kunststoffanwendungen an. Das Unternehmen unterhält strategische Allianzen mit Pfizer Inc. und eine Vereinbarung mit der Novartis AG sowie Lizenzvereinbarungen mit Debiopharm International SA und MoonLake Immunotherapeutics AG. Das Unternehmen wurde 1668 gegründet und hat seinen Hauptsitz in Darmstadt, Deutschland. Die MERCK Kommanditgesellschaft auf Aktien ist eine Tochtergesellschaft der E. Merck Kommanditgesellschaft.